Arcus Biosciences, Inc. (RCUS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 78 | 383 | 112 | 117 | 258 | 247 | 117 | 78 |
| Operating profit | $m | -386 | -486 | ||||||
| Net profit | $m | -123 | 53 | -267 | -307 | -283 | -353 | -452 | -440 |
| EPS reported | $ | -3.29 | -3.93 | ||||||
| Operating cashflow per share | $ | -4.49 | -3.76 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -4.51 | -3.77 | ||||||
| Free cash flow | $m | -484 | -475 | ||||||
| Net debt | $m | -882 | -588 | ||||||
| Book value equity | $m | 631 | 464 | ||||||
| Book value per share | $ | 5.88 | 3.68 | ||||||
| Number of shares | m | 107.4 | 126.1 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.06 | 5.52 | ||||||
| P/S LTM | x | 10.36 | 21.87 | ||||||
| P/FCF LTM | x | -5.29 | -5.39 | ||||||
| EV/EBITDA LTM | x | -7.31 | -5.85 | ||||||
| EV/Sales LTM | x | 9.92 | 31.38 | ||||||
| Earnings Yield LTM | % | -13.79% | -12.16% | ||||||
| FCF Yield | % | -18.91% | -18.56% | ||||||
| Quality | |||||||||
| ROE | % | -55.94% | -87.98% | ||||||
| ROIC | % | -41.91% | -65.76% | ||||||
| Operating margin | % | -1.56% | -4.15% | ||||||
| Gross margin | % | +95.95% | +94.02% | ||||||
| FCF/Sales | % | -195.95% | -405.98% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -4.26% | -54.65% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.32 | -4.17 | ||||||
| Net Debt/EBITDA | x | 0.33 | 0.09 | ||||||
| EBIT/Net interest | x | -48.25 | -21.13 | ||||||
| Net debt/market cap | % | +3.87% | +2.72% | ||||||
| Net debt/Equity | x | -1.40 | -1.27 | ||||||
| Gross debt/equity | x | 0.18 | 0.25 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free